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Summary  Despite  continuous  improvements  in  management  of  patients  with  cancer,  cardiac
side-effects  still  account  for  a  substantial  limitation  of  chemotherapy.  Evaluation  of  cardiac
toxicity in  patients  includes  consideration  of  biomarkers  such  as  cardiac  troponins  and  B-
type natriuretic  peptides,  together  with  non-invasive  imaging  in  the  form  of  2D-,  3D-,  or
strain-echocardiography,  multiple  gated  radionuclide  angiography,  quantitative  gated  blood-
pool SPECT, 123I-metaiodobenzylguanidine  scintigraphy,  or  cardiac  magnetic  resonance  imaging.
These approaches  differ  from  each  other  with  regards  to  availability,  accuracy,  sensitivity  to
detect early  stages  of  cardiac  injury,  individual  reliability,  ease  of  use  in  a  longitudinal  follow-up
perspective,  and  to  related  cost-effectiveness.  Improving  prevention  of  these  cardiac  side-
effects depends  on  several,  currently  unresolved  issues.  Early  detection  and  quantiﬁcation
of cardiac  damage  is  required  to  adapt  chemotherapy  in  progress  for  optimal  management  of
patients. Whether  increased  availability  of  myocardial  strain  imaging  and  repeat  blood  biomark-
ers determinations  will  reliably  and  consistently  achieve  these  goals  remain  to  be  conﬁrmed.
Also, protective  approaches  to  reduce  cardiac  toxicity  of  anticancer  drugs  should  be  reconside-
red according  to  the  recently  restricted  approval  for  use  of  dexrazoxane.  Anthracycline-based
regimens,  encapsulated  anthracyclines  and  non-anthracycline  regimens  should  be  revisited  with
Abbreviations: 123I-MIBG, iodine-123 metaiodobenzylguanidine; 2D, two-dimensional; 3D, three-dimensional; BNP, brain natriuretic pep-
tide; HER2, human epidermal growth factor receptor 2; LV, left ventricular; LVEF, left ventricular ejection fraction; MRI, magnetic resonance
imaging; MUGA, multigated radionuclide angiography; NT-proBNP, N-terminal pro-brain natriuretic peptide; ROS, reactive oxygen species;
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regards  to  antitumour  efﬁcacy  and  cardiac  toxicity.  Cardiovascular  drugs  that  proved  effec-
tive in  prevention  of  anthracycline-induced  cardiac  toxicity  in  experimental  models  should  be
investigated  in  clinical  trials.  Finally,  the  efﬁcacy  of  cardiovascular  drugs  that  have  already
been tested  in  clinical  settings  should  be  conﬁrmed  and  compared  with  each  other  in  patients
in increased  numbers.
© 2012  Published  by  Elsevier  Masson  SAS.
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Résumé  Malgré  les  progrès  de  la  prise  en  charge  des  malades  atteints  de  cancer,  les
effets secondaires  cardiaques  des  chimiothérapies  restent  un  facteur  limitant  non  négligeable.
L’évaluation  de  la  cardiotoxicité  en  cours  de  constitution  fait  appel  aux  biomarqueurs,  tro-
ponines et  peptides  natriurétiques,  ainsi  qu’à  l’imagerie  non  invasive,  échocardiographie  2D,
3D, de  strain,  ventriculographie  isotopique,  tomographie  d’émission  de  positons,  scintigraphie
à la  métaiodobenzylguanidine-123I  (MIBG)  ou  à  l’IRM.  Chacune  de  ces  méthodes  se  distingue  par
sa disponibilité,  sa  précision,  la  sensibilité  de  détection  des  lésions  cardiaques  débutantes,  sa
reproductibilité,  sa  simplicité  d’emploi  dans  le  cadre  d’une  surveillance  clinique  et  son  rapport
coût—efﬁcacité.  Améliorer  la  prévention  de  cette  cardiotoxicité  nécessite  de  pouvoir  surmonter
les contraintes  actuelles.  La  détection  précoce  et  la  quantiﬁcation  des  lésions  cardiaques  débu-
tantes sont  un  pré-requis  à  l’optimisation  des  traitements  en  cours,  mais  il  n’est  pas  encore
certain que  le  développement  rapide  de  l’échographie  de  strain  et  le  recours  régulier  aux
biomarqueurs  permettront  d’atteindre  pleinement  ces  objectifs.  Ce  d’autant  que  nos  méthodes
de cardioprotection  devront  être  revues,  en  aval  de  la  récente  restriction  d’emploi  du  dexra-
zoxane, qui  impacte  sur  les  protocoles  de  chimiothérapies  à  base  d’anthracyclines,  encapsulées
ou non,  ou  sur  leurs  alternatives,  en  fonction  des  cancers  et  des  malades  traités.  Un  certain
nombre de  médicaments  qui  ont  montré  une  efﬁcacité  dans  cette  prévention  sur  des  modèles
expérimentaux  devront  être  étudiés  dans  le  cadre  d’essais  cliniques,  en  particulier  les  médica-
ments cardiovasculaires  déjà  utilisés  dans  d’autres  indications  et  dont  la  cardioprotection  a
pu être  documentée  sur  des  études  préliminaires.  Leurs  résultats  devront  être  conﬁrmés  et
comparés  entre  eux  dans  des  études  à  plus  grande  échelle.
© 2012  Publié  par  Elsevier  Masson  SAS.
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espite  continuous  improvements  in  the  management  of
atients  with  cancer,  cardiac  side-effects  still  represent  a
ubstantial  drawback  of  chemotherapy.  Multiple  drug  pro-
ocols,  combination  regimens  and  adjuvant  and  targeted
herapies  administered  to  patients  in  increased  numbers
ave  resulted  in  signiﬁcant  improvements  in  prognosis  and
urvival,  but  these  have  been  blunted  by  several  disadvan-
ages  with  regard  to  cardiac  safety  [1—3]. In  turn,  detection
nd  prevention  of  these  complications  have  become  quite
outine  practice,  especially  in  patients  with  increased  risk,
uch  as  children,  the  elderly,  patients  with  coronary  artery
isease,  hypertension,  diabetes  or  a  history  of  smoking  and
hose  who  have  received  previous  anthracyclines  or  radia-
ion  therapy  [4,5].
Conventional  approaches  for  detecting  myocardial  dam-
ge  by  chemotherapy  using  two-dimensional  (2D)  echocar-
iography  or  radionuclide  ventriculography  have  recently
een  challenged  by  more  sophisticated  echocardiographic
echniques,  including  myocardial  strain  imaging  and  three-
imensional  (3D)  echocardiography.  Biochemical  methods
sing  cardiac  biomarkers  such  as  troponins  and  brain  natri-
retic  peptide  (BNP)  have  emerged  as  sensitive  tools  for
redicting  subsequent  cardiac  dysfunction.  Cardiovascular
agnetic  resonance  imaging  (MRI)  has  been  proven  to  be
ffective  and  reliable  in  monitoring  left  ventricular  (LV)
A
T
nunction  during  therapy.  In  addition,  MRI  can  be  used  to  char-
cterize  myocardial  tissue  and  to  identify  early  evidence  of
yocardial  injury.
However,  despite  increased  recognition  and  detection  of
he  cardiac  side-effects  of  anticancer  drugs,  prevention  has
ot  progressed  concomitantly.  As  a  result  of  recent  concerns
egarding  prevention  of  anthracycline-related  toxicity  with
exrazoxane,  strategies  for  cardiac  protection  should  be
evisited.  In  addition,  prevention  of  the  cardiac  side-effects
f  the  rapidly  expanding  spectrum  of  targeted  therapies
emains  at  the  planning  stage  and  should  be  implemented.
ardiac complications of anticancer drugs
dministration  of  cytotoxic  agents  and/or  targeted  thera-
ies  may  result  in  several  cardiac  complications,  including  LV
ysfunction,  heart  failure,  myocardial  ischaemia,  arrhyth-
ias  and  conduction  abnormalities,  depending  on  the  drug
r  regimen  administered  and  the  patient  being  treated.
eart failure and LV dysfunctionnthracyclines
hese  potent  anticancer  agents  act  by  intercalation  into
uclear  DNA,  inhibition  of  topoisomerase  II,  production  of
ther
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(Detection  and  prevention  of  cardiac  complications  of  chemo
reactive  oxygen  species  (ROS),  p53  binding  to  DNA  and
induction  of  apoptosis  [6,7].
Cardiac  side-effects  result  from  induction  of  oxidative
stress  and  apoptosis.  Electrons  released  by  an  anthra-
cycline  binding  to  DNA  generate  redox  cycling  of  the
quinone/semiquinone  form  of  the  drug,  which  interacts
with  iron  stores  to  produce  superoxide  anions  and  induce
the  proapoptotic  pathway.  Transgenic  mice  overexpress-
ing  the  superoxide  dismutase  and  nicotinamide  adenine
dinucleotide  phosphate  (NAD[P]H)  oxidase  knockout  mice
are  protected  against  anthracycline-induced  cardiotoxicity.
Similarly,  inhibition  of  the  proapoptotic  cascade  and  acti-
vation  of  the  antiapoptotic  cascade  in  animal  models  result
in  reduced  cardiac  toxicity  [1,3—7]. Pathways  involving  ROS
production  and  apoptosis  interact  with  each  other.  Injuries
to  mitochondrial  DNA  induced  by  ROS  elicit  proapoptotic
imbalance  [8],  which  is  also  enhanced  by  transmembrane
signalling  pathways  activating  Toll-like  receptors  and,  in
turn,  the  apoptotic  cascade  [9].  In  addition,  anthracyclines
have  recently  been  reported  to  damage  cardiac  progenitor
cells,  resulting  in  late/delayed  LV  dysfunction,  which  may
occur  10—20  years  after  anthracycline  treatment  in  children
[10,11].
Acute  heart  failure  is  an  uncommon  but  severe  cardiac
complication  of  anthracycline-based  regimens  and  pre-
dominantly  affects  children.  In  a  cohort  of  1697  patients
treated  for  non-Hodgkin’s  lymphoma,  acute  heart  failure
was  observed  in  only  0.2%  of  patients  whereas  dose-
dependent  progressive  heart  failure  developed  in  3.2%
during  therapy  [12].
Progressive  dose-dependent  cardiac  dysfunction  results
from  repeated  administration  of  anthracyclines.  Diastolic
dysfunction  has  been  reported  to  occur  with  cumulative
doses  of  200  mg/m2 doxorubicin,  followed  by  systolic  dys-
function  beyond  400—600  mg/m2,  with  individual  threshold
variability  [13,14].  Whereas  the  former  usually  remains
asymptomatic,  patients  with  systolic  dysfunction  often
present  with  signs  and  symptoms  of  heart  failure.  Among
3941  patients  treated  with  anthracyclines  in  the  study  by
Bristow  et  al.,  88  developed  symptomatic  heart  failure  dur-
ing  follow-up,  depending  on  the  cumulative  dose  they  were
given,  ranging  from  0.14%  of  those  who  received  less  than
400  mg/m2 to  7%  of  those  who  received  550  mg/m2 and  18%
of  those  who  received  more  than  700  mg/m2 [15].
Several  risk  factors  for  increased  cardiac  toxicity  have
been  identiﬁed,  including  older  age,  combination  with
cyclophosphamide,  trastuzumab  and  taxanes  (docetaxel,
paclitaxel),  and  mediastinal  irradiation.  Children  also  have
an  increased  risk.  In  a  follow-up  study  by  Lipshultz  et  al.,  32%
of  children  who  received  more  than  410  mg/m2 doxorubicin
equivalent  presented  with  some  degree  of  LV  dysfunction.
Also,  late/delayed  LV  dysfunction  several  years  after  com-
pletion  of  therapy  impairs  prognosis  in  5—10%  of  children
[16].
Other  cytotoxic  agents
The  alkylating  agent  cyclophosphamide  and  related  com-
pounds  such  as  ifosfamide  may  promote  LV  dysfunction
and  heart  failure,  especially  at  high  doses  or  in  combi-
nation  with  anthracyclines  or  cisplatin.  Heart  failure  has
also  been  reported  during  therapy  with  the  antimetabolites
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-ﬂuorouracil  and  its  prodrug  capecitabine,  as  well  as
ith  taxanes  (paclitaxel,  docetaxel)  and  other  microtubule
nhibitors,  all  of  which  increase  anthracycline-related
ardiac  toxicity.  The  combination  of  anthracyclines  and
axanes—a  standard  regimen  for  node-positive  breast
ancer—increases  cardiotoxicity  [2—4]. Sequential  combina-
ion  of  anthracyclines  and  cyclophosphamide  followed  by
rastuzumab  and  paclitaxel  in  patients  treated  for  human
pidermal  growth  factor  receptor  2  (HER2)-positive  breast
ancer  results  in  a  3-year  incidence  of  heart  failure  and  car-
iovascular  death  of  4.1%  compared  with  0.8%  in  patients
eceiving  anthracyclines  and  cyclophosphamide  only  [17].
yrosine  kinase  inhibitors
yrosine  kinase  (TK)  inhibitors  comprise  monoclonal  anti-
odies  directed  against  speciﬁc  malignant  cell  membrane
eceptors  associated  with  TK  activity  and  small  molecule
nhibitors  that  interact  with  the  intracellular  downstream
K  signalling  pathways.
Trastuzumab  is  a  humanized  monoclonal  antibody
irected  against  the  HER2  protein,  which  is  overexpressed
n  20—25%  of  breast  cancers.  Heart  failure  occurs  in  1—5%  of
atients  treated  with  trastuzumab  and  about  10%  present
ome  degree  of  LV  dysfunction  [18,19].  In  another  study,
symptomatic  LV  dysfunction  was  found  in  7.1%  of  patients
eceiving  trastuzumab  and  2.2%  of  controls,  whereas  symp-
omatic  LV  dysfunction  was  encountered  in  1.7%  vs  0.1%,
espectively  [20]. This  risk  is  increased  with  older  age,
oronary  artery  disease  and  combination  with  anthracy-
lines  or  cyclophosphamide.  In  a  review  of  seven  phase  II
nd  III  trastuzumab  clinical  trials,  the  incidence  of  cardiac
oxicity  depended  on  these  factors,  reaching  27%  in  combi-
ation  with  anthracyclines  or  cyclophosphamide,  13%  with
aclitaxel  and  only  3—7%  without  these  agents  [21]. In  a
-year  follow-up  of  48  patients  with  trastuzumab-induced
eart  failure,  Ewer  et  al.  showed  that  a  reduction  in  LV
jection  fraction  (LVEF)  occurred  within  a  few  days  after
rastuzumab  administration  in  patients  who  had  already
eceived  anthracyclines  (mean  LVEF  reduction  from  61%  to
1%).  Discontinuation  of  trastuzumab  was  associated  with
ubsequent  recovery  within  1—3  months.  Among  25  patients
n  whom  trastuzumab  was  readministered,  repeat  heart  fail-
re  or  LV  dysfunction  occurred  in  only  three  [22].
Clinical  characteristics  of  trastuzumab-induced  dysfunc-
ion  differ  from  those  of  anthracycline-induced  dysfunction,
s  they  are  often  transient.  Recurrences  are  seen  incon-
istently  (even  rarely)  with  subsequent  administrations.  In
ost  instances,  withdrawal  of  trastuzumab  allows  reversal
f  LVEF  decline.  By  contrast,  with  anthracycline-induced
yocardial  injuries  (myocyte  loss,  myoﬁbrillar  disarray,
acuoles),  ultrastructural  changes  are  not  observed  after
rastuzumab  administration.  Consistent  with  these  ﬁnd-
ngs,  a  revised  classiﬁcation  for  chemotherapy-induced
ardiac  dysfunction  has  been  proposed,  according  to  the
elated  mechanism,  damage  (anthracyclines)  or  dysfunction
trastuzumab)  [23].
LV  dysfunction  has  also  been  reported  in  patients
eceiving  bevacizumab,  an  immunoglobulin  G-targeting
ascular  endothelial  growth  factor  (VEGF)-A.  In  a  meta-
nalysis  by  Choueiri  et  al.,  which  included  3784  patients,
he  overall  incidences  of  symptomatic  heart  failure  in
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nary  artery  disease  [2,42]. An  increased  risk  of  acute
coronary  syndrome  was  also  seen  in  patients  receiving96  
evacizumab-  and  placebo-treated  patients  were  1.6%  and
.4%,  respectively.  The  relative  risk  of  heart  failure  in
atients  receiving  bevacizumab  was  4.74,  without  differ-
nce  in  incidence  of  risk  between  patients  treated  with
ow  or  high  doses  [24]. Heart  failure  was  more  frequent
n  bevacizumab-treated  patients  who  had  already  been
reated  with  anthracyclines  (14%)  or  had  mediastinal  irradi-
tion.  Of  note,  cardiac  dysfunction  occurred  only  in  patients
ho  had  presented  with  previous  bevacizumab-induced
ypertension  [18]. Alemtuzumab,  a  humanized  immunoglob-
lin  G  targeted  to  lymphocytes  through  the  CD52  receptor,
ay  also  induce  LV  dysfunction,  but  in  fewer  instances.
Small  molecule  TK  inhibitor-induced  LV  dysfunction  is
ncreasingly  recognized,  with  the  rapidly  expanding  panel
f  drugs  that  have  received  approval  for  use  as  therapy
or  a  large  variety  of  tumours.  Treatment  with  imatinib
esylate  has  been  reported  to  result  in  cardiac  mitochon-
rial  injuries  and,  in  a  few  case  reports,  in  LV  dysfunction
25,26].  Whether  imatinib  mesylate  induces  heart  failure  in
 signiﬁcant  subset  of  treated  patients  remains,  however,
nder  debate  [27,28].  Indeed,  in  a  retrospective  analy-
is  of  219  patients  with  gastrointestinal  stromal  tumours
nd  other  sarcomas  treated  with  imatinib  mesylate,  Trent
t  al.  showed  that  arrhythmias,  acute  coronary  syndromes
nd  congestive  heart  failure  were  uncommon,  occurring  in
ess  than  1%  of  patients  [28]. Also,  assessment  of  serial
lasma  NT-proBNP  and  serum  cardiac  troponin  T  measure-
ents  before  therapy,  then  1  and  3  months  after  the  start
f  therapy,  failed  to  demonstrate  increases  in  NT-proBNP
oncentrations,  indicating  that  the  risk  of  subclinical  car-
iotoxicity  also  remained  limited.  Only  one  patient  of  the
5  included  in  the  study  showed  increased  NT-proBNP  con-
entrations  and  developed  symptomatic  heart  failure  due
o  pre-existent  valvular  heart  disease  [29]. Although  LV  dys-
unction  induced  by  imatinib  mesylate  has  been  reversible
n  most  instances  after  discontinuation  of  therapy,  late  per-
istent  irreversible  heart  failure  has  also  been  reported
30,31].  Imatinib  mesylate-induced  cardiac  toxicity  is  also
acilitated  by  several  relevant  comorbidities,  such  as  previ-
us  cardiovascular  disease  or  renal  failure  [31].
Sunitinib  malate,  a  multitargeted  TK  inhibitor  acting
ainly  on  the  VEGF  receptor,  has  recently  been  approved  for
linical  use  in  patients  with  metastatic  renal  cell  carcinoma
nd  gastrointestinal  stromal  tumours;  its  administration
s  associated  with  progressive  asymptomatic  LV  dysfunc-
ion  in  28%  of  patients  and  symptomatic  heart  failure
n  2.7%.  Patients  with  coronary  artery  disease,  previous
V  dysfunction  and/or  LV  hypertrophy  and  patients  who
ave  already  received  anthracyclines  have  been  reported
o  be  at  increased  risk  and  should  be  carefully  moni-
ored  [1—6]. Whether  sunitinib-induced  LV  dysfunction  is
eversible  remains  uncertain.  Whereas  all  patients  recov-
red  after  cardiovascular  management  and  were  considered
ligible  for  TK  inhibitor  continuation  in  one  study  [32],
ther  studies  reached  more  controversial  conclusions,  as  LV
ysfunction  and  symptoms  persisted  in  a  small  subset  of
atients  [33]. Moreover,  some  asymptomatic  patients  had
ecurrent  LVEF  reductions  after  restarting  sunitinib  [34].Lapatinib,  a  small  molecule  targeting  HER2  and  epider-
al  growth  factor  receptor  (EGFR),  has  been  developed  as
n  alternative  to  trastuzumab  in  the  treatment  of  HER2-
ositive  breast  cancer.  First  trials  showed  that  1.6%  of
b
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atients  had  a  reduction  in  LVEF  of  more  than  20%  and
hat  0.2%  had  symptomatic  heart  failure.  Previous  ther-
py  with  anthracyclines  or  trastuzumab  was  associated  with
n  increased  risk  (2.2%  and  1.7%  vs  1.5%,  respectively)
35]. Phase  III  trials  also  showed  that  dasatinib,  a  small  TK
nhibitor  used  in  the  therapy  of  chronic  myeloid  leukaemia,
ay  induce  LV  dysfunction  in  about  2—4%  of  patients,  includ-
ng  50%  with  severe  heart  failure  [2].
roteasome  inhibitors
ortezomib,  a  novel  anticancer  agent  registered  for  multi-
le  myeloma,  acts  by  inhibition  of  proteasome,  activation
f  nuclear  factor  kappa  B  (NF-B) and,  in  turn,  induc-
ion  of  apoptosis.  Cardiovascular  complications  have  been
eported  in  a  few  case  reports  [36]  and  in  eight  of  a  series
f  69  patients  receiving  the  drug,  including  four  with  heart
ailure  [37]. Pathological  examinations  performed  in  ani-
als  showed  mitochondrial  changes,  decreased  adenosine
riphosphate  synthesis  and  reduced  cardiomyocyte  contrac-
ility  [38].
yocardial ischaemia
yocardial  ischaemia  is  a  frequent  and  potentially  harmful
ide-effect  in  patients  receiving  the  antimetabolite  agent
-ﬂuorouracil;  it  includes  asymptomatic  T-wave  changes,
hest  pain,  acute  coronary  syndromes  and  myocardial  infarc-
ion.  Acute  coronary  syndromes  have  been  reported  in
.6—7.6%  of  patients,  with  a  drug-related  cardiovascular
ortality  rate  as  high  as  2.2%.  The  incidence  of  cardiac
vents  in  patients  receiving  5-ﬂuorouracil  was  fourfold
n  those  who  had  prior  cardiac  disease,  especially  coro-
ary  artery  disease  [39]. Acute  coronary  syndromes  may
lso  occur  in  patients  with  normal  coronary  angiography.
oronary  artery  spasm  has  been  documented  in  a  few
ases.
Capecitabine,  the  ﬂuoropyrimidine  prodrug  of  5-
uorouracil,  may  also  promote  myocardial  ischaemia  and
entricular  arrhythmias  [40]. Although  previous  case  reports
uggested  that  these  complications  are  usually  reversible,
aution  is  required  in  patients  with  coronary  artery  dis-
ase,  in  whom  the  risk  is  increased,  and  in  patients  who  are
oncomitantly  treated  with  oxaliplatin.  Indeed,  major  car-
iac  events  occurred  in  6.5%  of  patients  who  were  treated
ith  this  combination  regimen,  including  sudden  death,
entricular  tachycardia  and  acute  coronary  syndromes
4.6%)  [41].
The  proteasome  inhibitor  bortezomib  has  been  reported
o  cause  atherosclerotic  plaque  progression  and  tendency
o  rupture,  thereby  promoting  acute  coronary  syndromes,
hich  have  been  reported  in  few  patients  [37]. Myocar-
ial  ischaemia  is  observed  in  0.29—0.5%  of  patients  treated
ith  paclitaxel  and  1.7%  of  those  receiving  docetaxel,
ainly  affecting  patients  with  a  past  history  of  coro-evacizumab  in  controlled  clinical  trials  (1.5%  vs  1%)  [18].
atients  treated  with  cisplatin,  sorafenib  (2.7%  vs  1.3%)
r  erlotinib  (2.3%  vs  1.2%)  are  also  at  increased  risk
2—4].
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ADetection  and  prevention  of  cardiac  complications  of  chemo
Arrhythmia and conduction disturbances
The  microtubule  inhibitors  paclitaxel  and  docetaxel  (tax-
anes)  induce  asymptomatic  sinus  bradycardia  in  29%  of
patients  and  more  severe  cardiac  complications  in  5%,
including  bradycardia-related  syncope,  ventricular  arrhyth-
mias  and  myocardial  ischaemia  [42].
Arrhythmias  have  been  reported  during  therapy  with
anthracyclines,  including  induced  atrial  ﬁbrillation,
supraventricular  and  ventricular  premature  beats  and/or
tachycardias  [12,13].  Interaction  with  cardiac  ion  channels
and  currents  are  considered  to  play  a  pivotal  role  in  the
genesis  of  these  arrhythmias,  as  well  as  in  the  occur-
rence  of  electrocardiographic  changes  such  as  QT  interval
prolongation  and  non-speciﬁc  T-wave  changes  [2,4,12,13].
Arsenic  trioxide,  a  drug  effective  in  acute  promyelocytic
leukaemia,  increases  the  QT  interval  in  50%  of  patients.
Several  cases  of  torsades  de  pointes  have  been  reported
[43].
Detection of cardiac complications
Evaluation  of  cardiac  toxicity  in  patients  treated  for  cancer
includes  consideration  of  blood  biomarkers  such  as  troponins
and  B-type  natriuretic  peptides,  together  with  non-invasive
imaging  in  the  form  of  2D-,  3D-  or  strain-echocardiography,
multigated  radionuclide  angiography  (MUGA),  quantita-
tive  gated  blood-pool  single-photon  emission  computed
tomography  (SPECT),  iodine-123  metaiodobenzylguanidine
(123I-MIBG)  scintigraphy  or  cardiac  MRI.  These  approaches
differ  from  each  other  with  regard  to  availability,  accuracy,
sensitivity  to  detecting  early  stages  of  cardiac  injury,  indi-
vidual  reliability,  ease  of  use  from  a  longitudinal  follow-up
perspective  and  cost-effectiveness.
Imaging techniques
Nuclear  cardiac  imaging
Serial  LVEF  determination  by  technitium-99m  MUGA  has  for
a  long  time  been  regarded  as  the  gold  standard  for  mea-
suring  cardiotoxicity  in  adult  patients.  Using  this  highly
reproducible  approach,  an  absolute  LVEF  less  than  50%  or
a  decrease  of  more  than  10%  from  baseline  have  been  rec-
ommended  for  discontinuation  of  anthracyclines  [44,45].
However,  as  alteration  of  LVEF  has  been  considered  as  a  too-
late  detector  of  myocardial  damage,  more  sensitive  methods
have  been  developed.
123I-MIBG  scintigraphy  images  the  efferent  sympathetic
nervous  innervations  of  the  heart  and  detects  changes  in
myocardial  adrenergic  innervations  before  LV  function  is
impaired.  Several  studies  showed  a  dose-dependent  decline
in 123I-MIBG  myocardial  uptake  in  patients  treated  with
anthracyclines  [44,46].
By  inhibiting  the  microtubular  transport  system,  the  tax-
anes  paclitaxel  and  docetaxel  impair  storage  of  free  fatty
acid  in  the  cytosolic  lipid  pool  of  cardiomyocytes,  resulting
in  reduced  mitochondrial  uptake  of  free  fatty  acids.  Myocar-
dial  perfusion  scintigraphy  with 123I-methylpentadecanoic
acid  (123I-BMIPP),  a  tracer  of  free  fatty  acids,  has  proven
effective  in  the  detection  of  early  myocardial  dysfunction
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ssociated  with  taxane  administration,  especially  when  tax-
nes  are  combined  with  carboplatin  [47].
More  sophisticated  radionuclide  imaging  techniques
rovide  potentially  useful  information.  Indium-111-
adiolabelled  trastuzumab  has  been  investigated  to
etect  myocardial  uptake  of  the  drug,  hypothesizing  that
rastuzumab-induced  cardiotoxicity  is  based  on  the  myocar-
ial  expression  of  HER2,  either  constitutively  or  after
nduction  by  pretreatment  with  anthracyclines  [44,48].
chocardiography
onventional  2D  echocardiography
onitoring  with  2D  echocardiography  is  the  technique
sed  most  frequently  in  clinical  practice.  Assessment  of
V  systolic  dysfunction  is  intended  to  detect  impairment
f  contraction  (reduced  interventricular  septum  motion,
hortening  fraction  reduced  by  more  than  20%),  which  usu-
lly  reﬂects  ongoing  cardiotoxicity  that  will  presumably
rogress  with  subsequent  administrations.  An  absolute  frac-
ional  shortening  less  than  26%  has  been  proposed  as  the
hreshold  below  which  anthracyclines  should  be  discontin-
ed  [49]. Similarly,  using  Simpson’s  biplane  method,  an
bsolute  LVEF  less  than  50%  or  a decrease  greater  than
0%  from  baseline  have  been  recommended  as  discon-
inuation  thresholds.  Unfortunately,  impairment  of  these
ariables  is  often  detected  only  after  considerable  cell
oss  has  taken  place  [50]. Considering  that  changes  in  sys-
olic  function  occur  too  late  to  allow  effective  prevention,
iastolic  function  has  been  investigated  to  see  whether
elaxation  measurements  can  predict  cardiotoxicity  at  an
arlier  stage.  Stoddart  et  al.  showed  that  most  patients
ho  develop  systolic  dysfunction  present  with  prior  impair-
ent  of  LV  diastolic  ﬁlling  Doppler  variables  at  cumulative
oses  as  low  as  120  mg/m2,  including  gradual  increases  in
sovolumetric  relaxation  time  and  E-wave  deceleration  time
14].
Detection  of  early  LV  dysfunction  has  also  been  proposed
sing  stress  echocardiography,  an  approach  that  demon-
trated  that  exercise-  and  dobutamine  infusion-induced
eductions  in  LV  posterior  wall  thickening  and  impairment
f  end-systolic  wall  strain  preceded  LV  systolic  dysfunction
n  patients  treated  with  anthracyclines.  Also,  a  fall  in  LV
ontractile  reserve  of  greater  than  ﬁve  units  during  a  low-
ose  dobutamine  stress  test  after  the  third  cycle  of  an
nthracycline-based  regimen  was  predictive  of  an  LVEF  less
han  50%  after  completion  of  therapy  [51].
However,  several  shortcomings  should  be  taken  into
ccount  when  using  these  approaches.  Resting  2D  echo-
ardiography  is  usually  late  in  detecting  cardiac  toxicity.
iastolic  measures  have  proven  difﬁcult  to  interpret  for
ndividual  monitoring.  Stress-coupled  examinations  are
ime-consuming  and  rarely  available  for  use  in  daily
ractice.
issue  Doppler  imaging  and  myocardial  strain  and  3D
chocardiography
ssessment  of  LVEF  in  patients  treated  for  cancer  has  been
ompared  using  2D  and  3D  echocardiography,  MUGA  and
ardiac  MRI.  Although  2D  echocardiography  demonstrates  a
eak  correlation  with  MRI  for  LVEF  evaluation  at  baseline
nd  during  follow-up,  both  3D  echocardiography  and  MUGA
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how  a  stronger  correlation  compared  with  cardiac  MRI
52].
Tissue  Doppler  imaging  (TDI)  has  also  been  proposed  as
 means  of  tracking  early  changes  in  cardiac  function.  In  a
mall  follow-up  study  of  patients  who  received  a  mean  doxo-
ubicin  cumulative  dose  of  227  mg/m2,  Tassan-Mangina  et  al.
eported  reduced  radial  and  longitudinal  relation  variables
Em)  and  reduced  maximal  velocity  of  systolic  myocardial
ave  (Sm),  whereas  systolic  function  variables  remained
nchanged  [53]. However,  despite  interesting  results  in  mice
odels  in  which  TDI  proved  useful  in  predicting  cardiotoxic-
ty,  the  use  of  TDI  in  humans  has  been  rather  disappointing.
ndeed,  TDI  performed  before  and  during  treatment  in  80
omen  receiving  epirubicin-based  chemotherapy  for  breast
ancer  failed  to  demonstrate  relevant  short-term  effects
f  low-dose  epirubicin  (mean  dose  274  mg/m2)  that  could
eliably  predict  subsequent  toxicity  [54].
Mercuro  et  al.  showed  that  early  impairment  of  systolic
unction  may  also  be  detected  using  strain  echocardiog-
aphy.  They  reported  a  signiﬁcantly  reduced  strain  rate
ppearing  for  cumulative  doses  as  low  as  200  mg/m2 epiru-
icin,  whereas  other  early  variables,  such  as  Em  or  Em/Am,
emained  unchanged  with  300  mg/m2 [55,56].  Similar  results
ere  obtained  in  children  by  Ganame  et  al.,  who  found
educed  peak  longitudinal  and  radial  systolic  strain  rate  and
train  after  completion  of  three  cycles  of  anthracycline-
ased  chemotherapy  [57].
Myocardial  deformation  imaging  using  2D-based  (speckle-
racking)  strain  and  strain  rate  has  also  been  proven  to
e  useful  in  monitoring  patients  receiving  trastuzumab,  in
hom  a  drop  of  at  least  one  standard  deviation  in  2D  longitu-
inal  strain  rate  was  predictive  of  a  subsequent  reduction  in
VEF  [58—60]. These  changes  were  supported  by  histological
ndings  in  an  animal  model,  in  which  strain  rate  more  sensi-
ively  detected  damage  in  myocardial  tissue  than  standard
chocardiographic  variables  [61].
ardiac  MRI
ardiac  MRI  can  be  used  to  evaluate  LV  performance  and
haracterize  myocardial  tissue.  However,  although  MRI  has
een  validated  as  being  more  accurate  and  reproducible  in
ssessing  LV  volumes  and  function  compared  with  2D  echo-
ardiography,  the  related  expenditure,  low  availability  and
equirement  for  trained  physicians  often  preclude  its  use  for
erial  monitoring  of  LVEF  in  a  daily  practice  setting  [50,52].
MRI  also  provides  additional  data  on  tissue  characteriza-
ion.  In  a  study  performed  in  patients  receiving  doxorubicin,
yocardial  oedema  was  seen  in  about  50%  of  patients,
ssociated  with  progressive  increases  in  LV  end-diastolic
iameter  and  volume  [62]. Another  study  showed  late
adolinium  enhancement  of  the  subepicardial  lateral  wall  in
0/160  patients  treated  with  trastuzumab  for  HER2-positive
reast  cancer  who  developed  drug-induced  cardiomyopathy.
f  note,  these  changes  persisted  after  discontinuation  of
rastuzumab  in  six  patients  in  whom  LV  function  recovered
63].  Similar  approaches  were  developed  in  animal  models  of
nthracycline  cardiotoxicity  to  determine  whether  changes
n  gadolinium  signal  intensity  on  T1-weighted  MRI  images—a
arker  of  myocardial  injury,  necrosis  or  ﬁbrosis—would  fore-
ast  a  subsequent  drop  in  or  preservation  of  LV  performance
64].
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iomarkers
iochemical  methods  of  detecting  and  monitoring  cardiac
ysfunction  or  injury  after  administration  of  anticancer
gents  have  been  developed  using  natriuretic  peptides  and
roponins.
atriuretic  peptides
NP  was  initially  considered  as  a  promising  marker  for  the
etection  of  chemotherapy-induced  cardiac  dysfunction.
owever,  although  Daugaard  et  al.  observed  increased  BNP
alues  in  patients  with  a  more  than  10%  reduction  in  LVEF,
ollow-up  of  patients  with  serial  BNP  measurements  failed  to
rove  reliable  usefulness,  as  neither  baseline  concentrations
or  subsequent  changes  during  therapy  were  predictive  of
 change  in  LVEF  [65]. Using  serial  plasma  N-terminal  pro-
rain  natriuretic  peptide  (NT-proBNP)  sampling  in  children
eceiving  anthracyclines,  Germanakis  et  al.  showed  higher
T-proBNP  concentrations  in  children  with  LV  mass  reduc-
ion  compared  with  in  those  in  whom  LV  mass  remained
nchanged  [66]. Similarly,  Kouloubinis  et  al.  demonstrated
 signiﬁcant  correlation  between  increased  concentrations
f  plasma  pro-atrial  natriuretic  peptide  and  NT-proBNP  and
 subsequent  decrease  in  LVEF  among  children  treated  with
pirubicin  [67].
NT-proBNP  has  also  been  evaluated  as  an  early  predic-
ive  marker  of  cardiac  dysfunction  in  patients  receiving
nthracyclines.  Cardinale  et  al.  determined  serial  plasma
T-proBNP  concentrations  during  a  72-hour  period  follow-
ng  chemotherapy  and  observed  three  different  patterns:  no
hange  in  NT-proBNP  concentration  in  the  six  serial  samples
31%  of  patients);  transient  increases  in  NT-proBNP,  with  con-
entrations  normalizing  within  72  hours  (35%  of  patients);
ersistent  elevation  of  NT-proBNP,  with  an  elevated  concen-
ration  at  72  hours  (33%  of  patients).  A  progressive  decline
n  LV  function  was  observed  in  the  third  group,  in  whom  LVEF
ecreased  from  66%  to  45%  during  the  subsequent  12  months
68].
Monitoring  follow-up  using  NT-proBNP  may  also  be  use-
ul  for  prognosis  classiﬁcation.  Gimeno  et  al.  stratiﬁed
atients  with  non-Hodgkin  lymphoma  with  regard  to  prog-
osis  according  to  their  baseline  NT-proBNP  concentration;
hey  showed  that  baseline  concentration  was  predictive  of
ubsequent  adverse  outcome  (death  from  any  cause,  includ-
ng  tumour  progression)  [69]. Although  these  ﬁndings  still
emain  unexplained  [70], they  provide  additional  support
or  natriuretic  peptide  monitoring  for  prognosis  stratiﬁca-
ion  and  treatment  optimization  in  some  instances,  such  as
reatment  of  lymphoma.
roponins
ardiac  troponins  are  sensitive  and  reliable  biochemical
arkers  of  myocardial  injury  in  patients  with  acute  coro-
ary  syndromes  and  myocarditis.  Troponin  I  has  also  been
ecognized  as  a  sensitive  marker  of  myocardial  damage  dur-
ng  cancer  chemotherapy.  Increases  in  troponin  I  occurring
uring  treatment  with  anthracyclines  were  reported  to  be
redictive  of  future  cardiac  dysfunction  [71], thereby  allow-
ng  prognosis  stratiﬁcation.  In  a  study  by  Cardinale  et  al.,
ultiple  blood  sampling  for  troponin  concentrations  dur-
ng  therapy  with  high-dose  anthracycline  regimens  showed
ther
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a  correlation  between  troponin  concentration  and  the  sub-
sequent  1-year  cardiovascular  event  rate  [72]. Patients  in
whom  the  troponin  I  concentration  remained  below  nor-
mal  values  after  each  cure  and  after  completion  of  therapy
(n  =  495)  were  at  very  low  risk  (<  1%  cardiovascular  events).
Patients  with  increased  troponin  concentrations  during  suc-
cessive  cures  and  after  completion  of  therapy  (n  =  63)  were
at  very  high  risk  of  cardiac  events  (84%).  Patients  with
increased  initial  values  but  troponin  concentrations  within
the  normal  range  after  therapy  completion  (n  =  165)  had  an
intermediate  risk  (37%).
Assessment  of  ongoing  cardiac  toxicity  using  serial
troponin  determinations  has  also  proven  useful  in  the  man-
agement  of  patients  treated  with  trastuzumab.  A  follow-up
study  performed  in  251  women  receiving  trastuzumab  for
HER2-positive  breast  cancer  showed  that  cardiac  toxic-
ity  (reduction  in  LVEF  of  >  10%  or  LVEF  <  50%),  observed
in  42  women  (17%),  was  more  frequent  in  those  with
elevated  troponin  I  concentrations  (62%  vs  5%).  Increases
in  troponin  concentrations  after  any  trastuzumab  treat-
ment  cycle  were  also  associated  with  a  reduced  LVEF
recovery  rate  (35%  vs  100%),  indicating  that  trastuzumab-
induced  increases  in  troponin  concentrations  predict  both
cardiac  toxicity  and  potential  recovery  of  LV  function
[73].
Prevention
Strategies  for  reducing  cardiac  toxicity  associated  with
anthracyclines  have  been  developed  using  two  different
approaches:  replacement  of  conventional  anthracyclines  by
liposomal  anthracyclines;  and  combination  of  anthracyclines
with  antioxidants  or  cardiovascular  drugs  (Table  1).
Liposomal anthracyclines
Liposome-encapsulated  anthracyclines  have  been  devel-
oped  to  more  speciﬁcally  target  tumour  cells  rather  than
cardiac  cells.  In  a  study  by  Heintel  et  al.,  non-pegylated
liposomal  doxorubicin  was  evaluated  in  37  patients  with
non-Hodgkin  lymphoma  and  pre-existing  cardiac  disease  or
elderly  patients  not  eligible  for  conventional  anthracyclines.
High  remission  rates  without  major  cardiac  toxicity  were
observed  in  this  high-risk  population  [74].
Pegylated  (polyethyleneglycol-encapsulated)  liposomal
doxorubicin  was  tested  as  an  adjuvant  therapy  in  older
women  with  breast  cancer.  In  a  study  by  Wildiers  et  al.,  car-
diac  follow-up  was  documented  using  Doppler-based  strain
imaging  and  2D  echocardiography  coupled  with  serial  deter-
minations  of  troponin  and  BNP  concentrations.  After  six
cycles  of  treatment,  LVEF  remained  unchanged,  while  sig-
niﬁcant  decreases  in  radial  strain  and  strain  rate  were
seen.  Although  the  study  was  not  intended  to  compare
cardiac  side-effects  between  pegylated  and  conventional
anthracyclines,  cardiac  toxicity  appeared  less  pronounced
with  the  pegylated  liposomal  regimen  [75]. Jurcut  et  al.
compared  strain  rate  imaging  and  conventional  echocardi-
ography  in  elderly  women  with  breast  cancer  who  received
pegylated  liposomal  doxorubicin.  Although  signiﬁcant  reduc-
tions  in  longitudinal  and  radial  strain  and  strain  rate  were
l
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ound  after  six  cycles  of  treatment,  LVEF  and  LV  dimensions
emained  unchanged  using  this  preventive  approach  [76].
The  ongoing  Liposomal  doxorubicin-Investigational
hemotherapy-Tissue  Doppler  imaging  Evaluation  (LITE)
tudy  intends  to  compare  LV  function  in  80  patients  with
reast  cancer  treated  with  either  liposomal  doxorubicin  or
tandard  epirubicin.  The  study  will  also  provide  clinical  and
echanistic  insights  into  the  potential  role  of  liposomal
nthracyclines  in  the  future  [77].
ntioxidants
revention  of  anthracycline-related  cardiac  toxicity  using
ntioxidant  drugs  has  been  supported  by  the  involvement  of
xidative  stress  in  inducing  this  myocardial  injury  [4,6—12].
Dexrazoxane,  a chelating  agent  that  limits  forma-
ion  of  anthracycline-iron  complexes  that  are  believed
o  generate  myocyte-damaging  free  radicals,  has  been
he  most  widely  used  compound.  Studies  performed  in
dults—mainly  women  treated  with  anthracyclines  for
reast  cancer—demonstrated  reduced  cardiac  toxicity  when
exrazoxane  was  also  used.  Combining  data  from  968
atients,  LVEF  reductions  were  less  common  in  women
eceiving  dexrazoxane  (1%  to  7.3%)  compared  with  in  con-
rols  (8%  to  23%)  [78,79].
Cardiac  cumulative  and  late-delayed  toxicity  is  also
 major  limiting  factor  in  children  treated  with  anthra-
yclines.  Lipshultz  et  al.  measured  serial  troponin  I
oncentrations  in  children  treated  with  doxorubicin  for
cute  leukaemia.  Increases  in  troponin  concentrations  were
bserved  in  21%  of  children  receiving  dexrazoxane  and  in
1%  of  controls  [80]. Another  study  in  75  children  treated
or  leukaemia  or  lymphoma  showed  fewer  late  (8  years)
mpairments  of  LVEF,  occurring  in  17%  of  those  who  received
exrazoxane  and  in  41%  of  controls  [81].
Unfortunately,  dexrazoxane  was  recently  shown  to
ncrease  the  risk  of  subsequent  malignancies,  myeloid
eukaemias  and  myelodysplastic  syndromes  in  patients  who
eceived  the  drug  in  combination  with  anthracyclines.
exrazoxane,  a  bisdioxopiperazine,  blocks  topoisomerase  II
urnover,  thereby  potentiating  doxorubicin-  and  etoposide-
nduced  impairment  of  DNA  repair.  Tebbi  et  al.  compared
ccurrences  of  such  second  malignant  diseases  among
hildren  treated  for  Hodgkin’s  disease,  with  (n  =  239)
r  without  (n  =  239)  combination  dexrazoxane.  The  chil-
ren  showed  an  increased  4-year  incidence  of  acute
yeloid  leukaemia/myelodysplastic  syndrome  (2.55%  vs
.85%)  and  second  malignant  neoplasms  (3.43%  vs  0.85%)
82].  Similarly,  Salzer  et  al.  showed  an  increased  sec-
nd  malignancy  rate  in  children  treated  for  lymphoblastic
eukaemias  who  received  dexrazoxane  [83]. In  light  of
hese  recent  concerns,  approval  for  the  use  of  dexra-
oxane  has  been  restricted  to  adults  only—mainly  women
reated  for  metastatic  breast  cancer  who  have  already
eceived  moderate-to-high  cumulative  doses  of  anthracy-
lines.Among  other  available  antioxidants,  probucol  (a  lipid-
owering  drug  with  antioxidant  properties)  has  been
eported  to  protect  against  anthracycline  cardiotoxicity  by
ctivating  superoxide  dismutase  and  glutathione  peroxidase
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Table  1  Potential  strategies  for  prevention  of  anthracycline-associated  cardiac  toxicity.
Reference  Animal  model
only
Evaluated  in
clinical  setting
Variables
analysed
Advantages  Shortcomings  Selected  population
Liposomal  anthracyclines
Non-pegylated  [74]  +  EF Received
approval  for  use
Pts  with  previous
anthracycline-based
regimen;  pts  with  heart
disease,  elderly  [74];
clinical  experience
currently  available
Pegylated  [75,76]  +  EF,  strain,  Tn,
BNP
Antioxidants
Dexrazoxane  [78—81]  +  EF,  Tn  AML,  dys-
myelopoietic
syndrome,
secondary
neoplasms
[82,83]  (use  in
children
abandoned)
Restricted  use  to
metastatic  breast
cancer  with  previous
anthracycline-based
regimen
Probucol  [84,95]  Activates
superoxide
dismutase  &
glutathione
peroxidase
— Enzymatic
activity
(myocyte
level)
Approved
lipid-lowering
drug
Cardiovascular  drugs
Iloprost  [87]  +  —  EF,  histology  Approved  Cost,
side-effects
Sildenaﬁl  [88]  +  —  Limits
apoptosis
Approved  Side-effects
Amlodipine  [85]  +  —  (+  expected
[86])
Limits
apoptosis
Approved  BP  Easy  to  apply  in  a  large
population
Carvediol  [89]  +  EF  Approved  HR,  BP
Enalapril  [90]  +  EF,  HF  Approved  BP,  renal
ﬁltration
Valsartan  [91]  +  EF  Approved  BP,  renal
ﬁltration
AML: acute myeloid leukaemia; BNP: brain natriuretic peptide; BP: blood pressure; EF: ejection fraction; HR: heart rate; pts: patients; Tn: troponins.
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in  animals.  However,  no  clinical  trial  has  been  performed  to
support  its  application  in  patients  [84].
Cardiovascular drugs
Several  cardiovascular  drugs  have  been  evaluated  for  their
potential  prevention  of  cardiac  toxicity  in  patients  receiving
anthracyclines.
Given  that  amlodipine  reduced  doxorubicin-induced  acti-
vation  of  caspase-3  and  cardiomyocyte  apoptosis  in  an
animal  model  [85], Outumoro  et  al.  suggested  that  calcium
channel  antagonists  should  be  routinely  added  to  anthracy-
clines  [86]. Similarly,  on  the  basis  of  doxorubicin-induced
cyclo-oxygenase  2  expression  and  its  protective  effects
on  related  cardiotoxicity  in  mice,  Neilan  et  al.  demon-
strated  a  protective  action  of  the  prostacycline  analogue
iloprost  [87]. In  animals,  protective  antiapoptotic  effects
have  been  shown  by  combining  anthracyclines  with  sil-
denaﬁl,  an  inhibitor  of  phosphodiesterase-5  that  decreases
caspase-3  activation,  mitochondrial  electrochemical  gradi-
ent  loss  and  the  resulting  induction  of  the  apoptotic  cascade
[88].  However,  this  approach  has  not  been  translated  into
clinical  practice.
Conversely,  several  studies  have  been  performed  in
patients  by  inhibiting  receptors  of  either  the  beta-
adrenergic  or  the  renin-angiotensin  system.  In  a  study  of  50
patients  receiving  doxorubicin  or  epirubicin  alone  or  in  com-
bination  with  carvedilol  12.5  mg  daily,  Kalay  et  al.  showed
that  LVEF  after  completion  of  therapy  was  higher  (69.9%  vs
52.3%)  in  patients  who  received  carvedilol.  Three  preven-
tive  mechanisms  are  advocated,  including  the  antioxidant
effects  of  the  drug,  activation  of  the  sarcoplasmic  reticu-
lum  calcium  adenosine  triphosphatase  or  inhibition  of  the
apoptotic  cascade  by  carvedilol  [89]. Inhibition  of  the  renin-
angiotensin  system  has  been  investigated  by  Cardinale  et  al.
in  114  patients.  After  a  1-year  follow-up,  anthracycline-
induced  LV  dysfunction  was  prevented  by  enalapril  20  mg
daily  in  56  patients  compared  with  in  58  controls  (62.4%  vs
48.3%).  Also,  fewer  patients  presented  with  symptomatic
heart  failure  (0%  vs  12%)  and  arrhythmias  (2%  vs  10%).
Reduced  ROS  production  has  been  reported  to  support  this
action  [90]. Inhibition  of  angiotensin  II  receptors  may  also
be  effective,  as  demonstrated  in  a  study  by  Nakamae  et  al.
involving  40  patients  treated  with  anthracyclines  for  non-
Hodgkin’s  lymphoma,  in  which  increases  in  LV  end-diastolic
diameter  were  prevented  in  those  who  received  valsartan
[91].
Targeted therapies
In  contrast  with  anthracyclines,  prevention  of  trastuzumab-
induced  LV  dysfunction  rather  depends  on  treatment
sequencing  than  on  drug  combinations  to  reduce  toxicity.
Indeed,  both  the  incidence  and  severity  of  trastuzumab-
induced  LV  impairment  are  increased  by  factors  such  as  age,
previous  cardiac  disease,  radiation  therapy  and  chemother-
apy  with  anthracyclines,  cyclophosphamide  and  paclitaxel.
Data  obtained  from  phase  II  and  III  trials  showed  that  con-
comitant  administration  of  trastuzumab  and  anthracyclines
dramatically  increases  toxicity,  thereby  suggesting  a  timely
separated  sequential  administration  [22,92].  The  National
Surgical  Adjuvant  Breast  and  Bowel  Project  (NSABP)  B31
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tudy  enrolled  1804  women  with  HER2-positive  breast  can-
er  and  an  LVEF  greater  than  50%  in  an  adjuvant  setting.
he  patients  received  four  cycles  of  an  anthracycline-based
egimen  followed  by  four  cycles  of  paclitaxel  and  were  sub-
equently  randomized  to  a  1-year  therapy  with  trastuzumab
r  placebo  starting  concurrently  with  paclitaxel.  LV  dysfunc-
ion  occurred  in  3.9%  of  women  treated  with  trastuzumab
nd  1.3%  of  controls.  Age,  therapy  for  hypertension  and  a
ildly  reduced  baseline  LVEF  (50—54%)  were  associated  with
n  increased  risk  [17]. In  the  European  Herceptin  Adjuvant
HERA)  trial,  trastuzumab  was  initiated  for  1  or  2  years  in
693  women,  several  months  after  the  anthracycline-based
egimen  was  completed.  Using  this  delayed-onset  approach,
he  incidence  of  trastuzumab  discontinuation  due  to  LV  dys-
unction  was  only  4.3%  [19]. Whereas  asymptomatic  LVEF
ecline  and  severe  heart  failure  were  more  frequent  in
omen  with  trastuzumab  than  in  controls  (3.04%  vs  0.53%
nd  2.15%  vs  0.12%,  respectively),  the  incidence  of  LV  dys-
unction,  as  in  the  NSABP  B31  trial,  was  substantially  lower
han  in  former  studies  in  which  no  delay  separated  comple-
ion  of  anthracycline  chemotherapy  and  trastuzumab  [17].
uidelines  for  trastuzumab  administration  have  recently
een  proposed,  in  which  therapy  is  delivered  on  the  basis  of
 persistent  LVEF  greater  than  50%  or  until  recovery  above
0%  after  3-week  intervals  of  drug  discontinuation,  when  a
ransient  decline  is  observed  [93].
As  combination  therapy  with  anthracycline-based  regi-
ens  and  trastuzumab  is  associated  with  increased  cardiac
oxicity,  non-anthracycline  regimens  with  trastuzumab  have
ecently  been  evaluated.  The  BCIRG  study  compared  doxo-
ubicin  and  cyclophosphamide  followed  by  docetaxel  with
r  without  trastuzumab  and  a  combination  of  carboplatin
nd  docetaxel  with  trastuzumab  in  3222  women  with
ER2-positive  breast  cancer.  While  adjuvant  trastuzumab
or  1  year  improved  disease-free  and  overall  survival,
he  risk-beneﬁt  ratio  favoured  the  non-anthracycline  reg-
men  over  the  anthracycline-based  regimen,  given  similar
fﬁcacy  and  reduced  cardiac  toxicity  [94]. Accordingly,
djuvant  trastuzumab  therapy  should  not  be  regarded  as
n  additional  risk  for  cardiac  toxicity  only,  but  also  as
ne  of  the  alternatives  to  design  regimens  intended  to
educe  anthracycline-induced  cardiac  side-effects  by  reduc-
ng  the  associated  anthracycline-dose  administered.  Such
n  approach  has  recently  been  investigated  in  an  ani-
al  model,  in  which  the  antioxidant  probucol  reduced
he  combined  toxicity  of  doxorubicin  and  trastuzumab
95].
LV  dysfunction  associated  with  bevacizumab  is  less
ommonly  encountered,  occurring  in  4%  of  unselected
atients.  Cardiac  dysfunction  occurs  mostly  in  patients  with
evacizumab-induced  hypertension,  of  whom  9.2%  have
evere  hypertension.  Patients  who  have  already  received
nthracyclines  have  an  increased  risk  (14%).  Severe  LV  dys-
unction  and  heart  failure  affect  0.3%  of  patients  only  [96].
ccordingly,  control  of  blood  pressure  level  should  be  con-
idered  as  a  ﬁrst-line  approach  to  prevent  LV  impairment.
lood  pressure  control  has  also  been  emphasized  in  the  man-
gement  of  patients  receiving  sunitinib  and  sorafenib,  which
ay  elicit  severe  hypertension  in  6.9%  and  7.2%,  respec-
ively  [96]. In  a  recent  study,  amlodipine  5  mg  daily  provided
ffective  blood  pressure  control  in  88.5%  of  patients  treated
ith  bevacizumab  [97].
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mproving  prevention  of  the  cardiac  side-effects  of  can-
er  chemotherapy  depends  on  several  currently  unresolved
ssues.  Early  detection  and  quantiﬁcation  of  cardiac  dam-
ge  is  required  to  adapt  chemotherapy  in  progress  and
or  optimal  management  of  patients.  Whether  increased
vailability  of  myocardial  strain  imaging  and  repeat  blood
iomarker  determinations  will  reliably  and  consistently
chieve  these  goals  remain  to  be  conﬁrmed.  Also,  protec-
ive  approaches  to  reduce  the  cardiac  toxicity  of  anticancer
rugs  should  be  reconsidered  given  the  recent  withdrawal
f  dexrazoxane.  Anthracycline-based  regimens,  encapsu-
ated  anthracyclines  and  non-anthracycline  regimens  should
e  revisited  for  antitumour  efﬁcacy  and  cardiac  toxic-
ty.  Cardiovascular  drugs  that  have  proved  effective  in
he  prevention  of  anthracycline-induced  cardiac  toxicity  in
xperimental  models  should  be  investigated  in  clinical  tri-
ls.  Finally,  the  efﬁcacy  of  cardiovascular  drugs  that  have
lready  been  tested  in  clinical  settings  should  be  conﬁrmed
nd  compared  in  larger  numbers  of  patients.
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